Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T15:51:00.236Z.
Calculation as of: 2026-10-06T15:51:00.236Z.
Quote observation: 2026-10-06T15:50:06.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: de430a97f2ce1d56e5593aeaf7513a4829955f1ae9df1fe435740c279e59bff8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
Hemab Therapeutics Holdings, Inc. Common Stock
Market Cap
$1.37B
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.35B
Free Cash Flow Yield
N/A
TTM Avg
45.28%
3Y Avg
45.08%
5Y Avg
45.08%
Market Cap
$1.41B
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.41B
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.42B
Free Cash Flow Yield
1.83%
TTM Avg
2.56%
3Y Avg
2.52%
5Y Avg
2.50%
Market Cap
$1.44B
Free Cash Flow Yield
1.26%
TTM Avg
0.66%
3Y Avg
0.66%
5Y Avg
1.32%
Market Cap
$1.44B
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.46B
Free Cash Flow Yield
10.40%
TTM Avg
10.16%
3Y Avg
6.41%
5Y Avg
5.78%
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG) | $1.37B | N/A | N/A | N/A | N/A |
| Omeros Corporation (OMER)vs › | $1.35B | N/A | 45.28% | 45.08% | 45.08% |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.41B | N/A | N/A | N/A | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.41B | N/A | N/A | N/A | N/A |
| The Pennant Group, Inc. (PNTG)vs › | $1.42B | 1.83% | 2.56% | 2.52% | 2.50% |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.33B | N/A | N/A | N/A | N/A |
| AnaptysBio, Inc. (ANAB)vs › | $1.44B | 1.26% | 0.66% | 0.66% | 1.32% |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.44B | N/A | N/A | N/A | N/A |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 10.40% | 10.16% | 6.41% | 5.78% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.48B | N/A | N/A | N/A | N/A |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
